Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.…
Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Equillium (NASDAQ: EQ) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 1.060 USD on 20 November 2026, down 3.6% over 52 weeks. Its 52-week range is 0.7600 USD to 3.540 USD: the price is 70.1% below the high and 39.5% above the low.
Its market capitalisation is 87.26M USD.
Equillium reports return on equity of -78.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 56.58M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 2 March 2027.